You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Stomach and esophageal disorders
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:diseases:gerd [10.17.2018] – [Patients experiences] sallieqhome:diseases:gerd [09.14.2022] (current) – external edit 127.0.0.1
Line 15: Line 15:
 Gastroesophageal reflux disease (GERD) is a condition in which the stomach contents (food or liquid) leak backwards from the stomach into the esophagus. This action can irritate the esophagus, causing heartburn and other symptoms. Gastroesophageal reflux disease (GERD) is a condition in which the stomach contents (food or liquid) leak backwards from the stomach into the esophagus. This action can irritate the esophagus, causing heartburn and other symptoms.
  
-Interestingly, the presence of //Helicobacter pylori// may be inversely related with GERD.(({{pubmed>long:21029801}})) It is unclear what the implications of this work are, however, patients on the Marshall Protocol should expect symptoms of GERD to improve on the treatment.+Interestingly, the presence of //Helicobacter pylori// may be inversely related with GERD.(({{pmid>long:21029801}})) It is unclear what the implications of this work are, however, patients on the Marshall Protocol should expect symptoms of GERD to improve on the treatment.
  
  
Line 33: Line 33:
 An antacid is any substance, generally a base or basic salt, which counteracts stomach acidity. Antacids are not contraindicated for Marshall Protocol (MP) patients. As with other over-the-counter medications and supplements, users should follow label directions carefully. An antacid is any substance, generally a base or basic salt, which counteracts stomach acidity. Antacids are not contraindicated for Marshall Protocol (MP) patients. As with other over-the-counter medications and supplements, users should follow label directions carefully.
  
-Note, however, that according to a recent literature review, antacids are no better than placebo in a literature review.(({{pubmed>long:16181387}})) +Note, however, that according to a recent literature review, antacids are no better than placebo in a literature review.(({{pmid>long:16181387}})) 
  
 MP patients should not take antacids at least one hour before or two hours after taking other medications. MP patients should not take antacids at least one hour before or two hours after taking other medications.
Line 41: Line 41:
 Proton-pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available today.  Proton-pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available today. 
  
-PPIs fall into the category of drugs that can be used for temporary relief of intolerable symptoms, but should be weaned when possible. The most troubling aspect of PPIs is their effect on the body's susceptibility to infection. A 2011 systematic review of the literature concluded that the severe hypochlorhydria (lack of stomach acid) generated by PPIs use leads to "bacterial colonisation and increased susceptibility to enteric bacterial infection."(({{pubmed>long:21999643}})) The adjusted [[http://en.wikipedia.org/wiki/Relative_risk|relative risk]] range for each microbe was calculated as follows.+PPIs fall into the category of drugs that can be used for temporary relief of intolerable symptoms, but should be weaned when possible. The most troubling aspect of PPIs is their effect on the body's susceptibility to infection. A 2011 systematic review of the literature concluded that the severe hypochlorhydria (lack of stomach acid) generated by PPIs use leads to "bacterial colonisation and increased susceptibility to enteric bacterial infection."(({{pmid>long:21999643}})) The adjusted [[https://en.wikipedia.org/wiki/Relative_risk|relative risk]] range for each microbe was calculated as follows.
   * //Salmonella// (4.2-8.3, e.g., 320% to 730% greater risk of infection)    * //Salmonella// (4.2-8.3, e.g., 320% to 730% greater risk of infection) 
   * //Campylobacter jejuni,// (3.5-11.7)   * //Campylobacter jejuni,// (3.5-11.7)
Line 107: Line 107:
  
  
-{{tag>diseases }}+{{tag>disease }} 
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
-===== References =====+===== References =====</nodisp> 
home/diseases/gerd.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.